Early Access to Medicines Scheme scientific opinion: Pemigatinib in the treatment of cholangioarcinoma

The MHRA has approved pemigatinib for use, prior to product licence and according to the criteria stipulated in the EAMS, for the treatment of adults with locally advanced relapsed or refractory metastatic cholangiocarcinoma with FGFR2 fusion or rearrangement.

Source:

Medicines and Healthcare products Regulatory Agency